---
figid: PMC8748807__41398_2021_1778_Fig1_HTML
figtitle: Proposed mechanisms of antipsychotic-induced metabolic side effects
organisms:
- Saccharomyces cerevisiae
- Vitex negundo
- Picrasma quassioides
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8748807
filename: 41398_2021_1778_Fig1_HTML.jpg
figlink: /pmc/articles/PMC8748807/figure/Fig1/
number: F1
caption: Antipsychotic drugs (e.g., olanzapine) increase plasma levels of l-glutamine
  (Gln) and l-leucine (Leu), two validated activators of the mTOR pathway. Gln and
  Leu are transported into hepatocytes by amino acid transporter solute carrier (SLC)
  SLC38A2 and SLC7A5, respectively. High levels of Gln and Leu cause a pseudo-fasted
  state, and activate the hepatic mTOR pathway. Activation of mTORC1 disturbs lipid
  and glucose metabolism, leading to upregulated lipid synthesis, accumulation of
  triglycerides, storage of nutrients, hyperlipidemia, glucose intolerance, weight
  gain, MetS, and other metabolic side effects. 4EBP1 eukaryotic initiation factor
  4E-binding protein 1, Gln l-glutamine, Leu l-Leucine, mTORC1 the mammalian target
  of rapamycin complex 1, MetS metabolic syndrome, pS6 ribosomal protein S6, p70s6K/S6K1
  p70S6 kinase, SLC38A2 solute carrier 38A2, SLC7A5 solute carrier 7A5.
papertitle: 'Mechanistic/mammalian target of rapamycin and side effects of antipsychotics:
  insights into mechanisms and implications for therapy.'
reftext: Chuanjun Zhuo, et al. Transl Psychiatry. 2022;12:13.
year: '2022'
doi: 10.1038/s41398-021-01778-w
journal_title: Translational Psychiatry
journal_nlm_ta: Transl Psychiatry
publisher_name: Nature Publishing Group UK
keywords: Psychiatric disorders | Schizophrenia
automl_pathway: 0.879271
figid_alias: PMC8748807__F1
figtype: Figure
redirect_from: /figures/PMC8748807__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8748807__41398_2021_1778_Fig1_HTML.html
  '@type': Dataset
  description: Antipsychotic drugs (e.g., olanzapine) increase plasma levels of l-glutamine
    (Gln) and l-leucine (Leu), two validated activators of the mTOR pathway. Gln and
    Leu are transported into hepatocytes by amino acid transporter solute carrier
    (SLC) SLC38A2 and SLC7A5, respectively. High levels of Gln and Leu cause a pseudo-fasted
    state, and activate the hepatic mTOR pathway. Activation of mTORC1 disturbs lipid
    and glucose metabolism, leading to upregulated lipid synthesis, accumulation of
    triglycerides, storage of nutrients, hyperlipidemia, glucose intolerance, weight
    gain, MetS, and other metabolic side effects. 4EBP1 eukaryotic initiation factor
    4E-binding protein 1, Gln l-glutamine, Leu l-Leucine, mTORC1 the mammalian target
    of rapamycin complex 1, MetS metabolic syndrome, pS6 ribosomal protein S6, p70s6K/S6K1
    p70S6 kinase, SLC38A2 solute carrier 38A2, SLC7A5 solute carrier 7A5.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HTL
  - SLC7A5
  - CRTC1
  - MTOR
  - RPTOR
  - EIF4EBP1
  - TAS2R63P
  - RPS6KB1
  - ETV3
  - Crtc
  - Tor
  - Thor
  - S6k
  - side
  - Sidpn
---
